288 related articles for article (PubMed ID: 14576047)
1. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group.
Sanz MA; Martín G; González M; León A; Rayón C; Rivas C; Colomer D; Amutio E; Capote FJ; Milone GA; De La Serna J; Román J; Barragán E; Bergua J; Escoda L; Parody R; Negri S; Calasanz MJ; Bolufer P;
Blood; 2004 Feb; 103(4):1237-43. PubMed ID: 14576047
[TBL] [Abstract][Full Text] [Related]
2. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group.
Ortega JJ; Madero L; Martín G; Verdeguer A; García P; Parody R; Fuster J; Molines A; Novo A; Debén G; Rodríguez A; Conde E; de la Serna J; Allegue MJ; Capote FJ; González JD; Bolufer P; González M; Sanz MA;
J Clin Oncol; 2005 Oct; 23(30):7632-40. PubMed ID: 16234524
[TBL] [Abstract][Full Text] [Related]
3. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia.
Sanz MA; Vellenga E; Rayón C; Díaz-Mediavilla J; Rivas C; Amutio E; Arias J; Debén G; Novo A; Bergua J; de la Serna J; Bueno J; Negri S; Beltrán de Heredia JM; Martín G
Blood; 2004 Dec; 104(12):3490-3. PubMed ID: 15292063
[TBL] [Abstract][Full Text] [Related]
4. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group.
Sanz MA; Montesinos P; Vellenga E; Rayón C; de la Serna J; Parody R; Bergua JM; León A; Negri S; González M; Rivas C; Esteve J; Milone G; González JD; Amutio E; Brunet S; García-Laraña J; Colomer D; Calasanz MJ; Chillón C; Barragán E; Bolufer P; Lowenberg B
Blood; 2008 Oct; 112(8):3130-4. PubMed ID: 18664623
[TBL] [Abstract][Full Text] [Related]
5. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis.
Montesinos P; Díaz-Mediavilla J; Debén G; Prates V; Tormo M; Rubio V; Pérez I; Fernández I; Viguria M; Rayón C; González J; de la Serna J; Esteve J; Bergua JM; Rivas C; González M; González JD; Negri S; Brunet S; Lowenberg B; Sanz MA
Haematologica; 2009 Sep; 94(9):1242-9. PubMed ID: 19608685
[TBL] [Abstract][Full Text] [Related]
6. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group.
Sanz MA; Martín G; Rayón C; Esteve J; González M; Díaz-Mediavilla J; Bolufer P; Barragán E; Terol MJ; González JD; Colomer D; Chillón C; Rivas C; Gómez T; Ribera JM; Bornstein R; Román J; Calasanz MJ; Arias J; Alvarez C; Ramos F; Debén G
Blood; 1999 Nov; 94(9):3015-21. PubMed ID: 10556184
[TBL] [Abstract][Full Text] [Related]
7. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group.
Lo-Coco F; Avvisati G; Vignetti M; Breccia M; Gallo E; Rambaldi A; Paoloni F; Fioritoni G; Ferrara F; Specchia G; Cimino G; Diverio D; Borlenghi E; Martinelli G; Di Raimondo F; Di Bona E; Fazi P; Peta A; Bosi A; Carella AM; Fabbiano F; Pogliani EM; Petti MC; Amadori S; Mandelli F;
Blood; 2010 Oct; 116(17):3171-9. PubMed ID: 20644121
[TBL] [Abstract][Full Text] [Related]
8. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.
Sanz MA; Montesinos P; Rayón C; Holowiecka A; de la Serna J; Milone G; de Lisa E; Brunet S; Rubio V; Ribera JM; Rivas C; Krsnik I; Bergua J; González J; Díaz-Mediavilla J; Rojas R; Manso F; Ossenkoppele G; González JD; Lowenberg B;
Blood; 2010 Jun; 115(25):5137-46. PubMed ID: 20393132
[TBL] [Abstract][Full Text] [Related]
9. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.
Esteve J; Escoda L; Martín G; Rubio V; Díaz-Mediavilla J; González M; Rivas C; Alvarez C; González San Miguel JD; Brunet S; Tomás JF; Tormo M; Sayas MJ; Sánchez Godoy P; Colomer D; Bolufer P; Sanz MA;
Leukemia; 2007 Mar; 21(3):446-52. PubMed ID: 17205057
[TBL] [Abstract][Full Text] [Related]
10. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
Iland HJ; Bradstock K; Supple SG; Catalano A; Collins M; Hertzberg M; Browett P; Grigg A; Firkin F; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
Blood; 2012 Aug; 120(8):1570-80; quiz 1752. PubMed ID: 22715121
[TBL] [Abstract][Full Text] [Related]
11. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups.
Mandelli F; Diverio D; Avvisati G; Luciano A; Barbui T; Bernasconi C; Broccia G; Cerri R; Falda M; Fioritoni G; Leoni F; Liso V; Petti MC; Rodeghiero F; Saglio G; Vegna ML; Visani G; Jehn U; Willemze R; Muus P; Pelicci PG; Biondi A; Lo Coco F
Blood; 1997 Aug; 90(3):1014-21. PubMed ID: 9242531
[TBL] [Abstract][Full Text] [Related]
12. Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia.
Iland H; Bradstock K; Seymour J; Hertzberg M; Grigg A; Taylor K; Catalano J; Cannell P; Horvath N; Deveridge S; Browett P; Brighton T; Chong L; Springall F; Ayling J; Catalano A; Supple S; Collins M; Di Iulio J; Reynolds J;
Haematologica; 2012 Feb; 97(2):227-34. PubMed ID: 21993673
[TBL] [Abstract][Full Text] [Related]
13. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy.
Montesinos P; González JD; González J; Rayón C; de Lisa E; Amigo ML; Ossenkoppele GJ; Peñarrubia MJ; Pérez-Encinas M; Bergua J; Debén G; Sayas MJ; de la Serna J; Ribera JM; Bueno J; Milone G; Rivas C; Brunet S; Löwenberg B; Sanz M
J Clin Oncol; 2010 Aug; 28(24):3872-9. PubMed ID: 20625122
[TBL] [Abstract][Full Text] [Related]
14. [Acute promyelocytic leukemia: results of the Chilean protocol LPA2000].
Undurraga MS; Puga B; Cabrera ME; Palma T; Rossle A; Vergara CG; Rojas B; Aspillaga A
Rev Med Chil; 2013 Oct; 141(10):1231-9. PubMed ID: 24522350
[TBL] [Abstract][Full Text] [Related]
15. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up.
Avvisati G; Petti MC; Lo-Coco F; Vegna ML; Amadori S; Baccarani M; Cantore N; Di Bona E; Ferrara F; Fioritoni G; Gallo E; Invernizzi R; Lazzarino M; Liso V; Mariani G; Ricciuti F; Selleri C; Sica S; Veneri D; Mandelli F;
Blood; 2002 Nov; 100(9):3141-6. PubMed ID: 12384411
[TBL] [Abstract][Full Text] [Related]
16. Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL).
Gupta V; Yi QL; Brandwein J; Lipton JH; Messner HA; Schuh AC; Wells RA; Minden MD
Leuk Res; 2005 Jan; 29(1):113-4. PubMed ID: 15541484
[TBL] [Abstract][Full Text] [Related]
17. High efficacy and low toxicity of APL induction with concurrent idarubicin/ATRA followed by a novel and simplified outpatient post-remission therapy using single doses of idarubicin and intermittent ATRA.
Aljurf M; Al Qurashi F; Al Mohareb F; Sahovic E; Al Sharif F; Al Zahrani H; Al Shanqeeti A; Owaidah T; Iqbal A; Zaidi SZ; Nurgat ZA; Sanz M; Chaudhri N
Med Oncol; 2010 Sep; 27(3):702-7. PubMed ID: 19669610
[TBL] [Abstract][Full Text] [Related]
18. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.
de la Serna J; Montesinos P; Vellenga E; Rayón C; Parody R; León A; Esteve J; Bergua JM; Milone G; Debén G; Rivas C; González M; Tormo M; Díaz-Mediavilla J; González JD; Negri S; Amutio E; Brunet S; Lowenberg B; Sanz MA
Blood; 2008 Apr; 111(7):3395-402. PubMed ID: 18195095
[TBL] [Abstract][Full Text] [Related]
19. Treatment of acute promyelocytic leukaemia using a combination of all-trans retinoic acid and chemotherapy.
Koh LP; Goh YT; Teoh G; Tan P
Ann Acad Med Singap; 2001 Jul; 30(4):401-8. PubMed ID: 11503549
[TBL] [Abstract][Full Text] [Related]
20. Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients.
Dai CW; Zhang GS; Shen JK; Zheng WL; Pei MF; Xu YX; Cao YX; Yi Y; Yang JJ; Peng HL; Zhong HY; Li RJ
Acta Haematol; 2009; 121(1):1-8. PubMed ID: 19246888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
